Eli Lilly and Company (LLY.MX)
| Previous close | 16,175.00 |
| Open | 16,071.01 |
| Bid | 15,754.21 x 100 |
| Ask | 0.00 x 10000 |
| Day's range | 16,071.01 - 16,071.01 |
| 52-week range | 7,452.75 - 16,799.99 |
| Volume | |
| Avg. volume | 242 |
| Market cap | 15.429T |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 128.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 95.34 (0.59%) |
| Ex-dividend date | 15 May 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the a
- PR Newswire
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. The efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on liver histology
- PR Newswire
Lilly announces departure of Anat Ashkenazi, chief financial officer
Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.
